Cadefrecitinib

Cadefrecitinib
Clinical data
Other namesGLPG3667
Identifiers
  • 4-methyl-5-[3-methyl-7-[(6-morpholin-4-ylpyridazin-3-yl)amino]imidazo[4,5-b]pyridin-5-yl]oxypyridine-2-carbonitrile
CAS Number
PubChem CID
IUPHAR/BPS
UNII
ChEMBL
Chemical and physical data
FormulaC22H21N9O2
Molar mass443.471 g·mol−1
3D model (JSmol)
  • CC1=CC(=NC=C1OC2=NC3=C(C(=C2)NC4=NN=C(C=C4)N5CCOCC5)N=CN3C)C#N
  • InChI=InChI=1S/C22H21N9O2/c1-14-9-15(11-23)24-12-17(14)33-20-10-16(21-22(27-20)30(2)13-25-21)26-18-3-4-19(29-28-18)31-5-7-32-8-6-31/h3-4,9-10,12-13H,5-8H2,1-2H3,(H,26,27,28)
  • Key:GXELZXDURVDKHP-UHFFFAOYSA-N

Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus. It is a TYK2 kinase inhibitor.[1][2][3]

References

  1. ↑ "Cadefrecitinib - Lakefront Biotherapeutics". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Mammoliti O, Martina S, Claes P, Coti G, Blanque R, Jagerschmidt C, et al. (June 2024). "Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry. 67 (11): 8545–8568. doi:10.1021/acs.jmedchem.4c00769. PMC 11181332. PMID 38805213.
  3. ↑ Han SJ, Jung GY, Lee GC, Ki DH, Kim BS (May 2026). "Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis". Biomolecules & Therapeutics. 34 (3). Seoul: 519–529. doi:10.4062/biomolther.2026.019. PMC 13149041. PMID 42059024.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.